APMD

16.0906.70%
PJ

Paul J. Sekhri

CEO, President & Chairman of the Board

Mr. Paul J. Sekhri serves as Chairman since October 15, 2026 at iOnctura SA. He serves as Chief Executive Officer, President & Chairman of the Board at vTv Therapeutics Inc. since April 2024. At the firm, he also served as Chief Executive Officer, President & Director from August 2022 to April 2024. He is Co-Founder of Aditum Bio Management Company, LLC. He serves as Petrichor Operating Partner at Petrichor Healthcare Capital Management LP since 2026, Executive Partner at Syncona Investment Management Limited since June 2026, Independent Chair of the Board at Apnimed, Inc. since June 2, 2026, Director at Deep Genomics Inc. since October 2025, Director at KayoThera, Inc. since July 2025, Director at AdhereTech Inc. since February 7, 2024, Independent Director at Veeva Systems Inc. since July 2014, Director at APT Pharmaceuticals, Inc. since December 2007 and Trustee at Cancer Research Institute, Inc. since October 2007. Mr. Sekhri also serves as Chair of Resolution Therapeutics Limited, Executive Chairman of Violet Therapeutics, Inc., Chairman of the Board at Petra Pharma Corporation, Chairman of the Board of Young Concert Artists, Director at Ascendancy Healthcare, Inc., Director at PreferredTime, Inc., Director at LikeMinds, Inc./DE, Venture Partner at Amana Global Partners FZ LLC, Advisor at Epidarex Capital and as an Advisory Board Member at Nodenza Venture Management, LLC. He serves as Independent Chairman of the Board at Longboard Pharmaceuticals, Inc. since February 2021, where he also served as Director from December 2020 to February 2021. He is a Member of the Business Advisory Board of Excision BioTherapeutics, Inc. since November 2020. Mr. Sekhri served as Independent Chairman of the Board at Compugen Ltd. from October 2017 to September 2025 and as Director at Quercis Pharma AG until 2025. He was an Independent Director at Ipsen S.A. from 2018 to 2023 and served at Pharming Group N.V. from 2015 to 2023, where his roles included Independent Non-Executive Director and Independent Non-Executive Chairman. He was an Independent Director at Axcella Health Inc. from May 2022 to November 2023. He served as Chief Executive Officer, President & Director at eGenesis, Inc. from January 2019 to April 2022. He was an Independent Director at BiomX Inc. from October 2020 to March 2022 and at Alpine Immune Sciences, Inc. from July 2017 to December 2020. He served as Chief Executive Officer, President and Director at Lycera Corp. from February 2015 to February 2019. His prior roles also include Venture Partner at Medicxi Ventures (UK) LLP; Operating Partner at Highline Therapeutics; Independent Director at Enumeral Biomedical Holdings, Inc.; Director at Nivalis Therapeutics, Inc.; Chairman of the Board at Topas Therapeutics GmbH; Managing Director and Operating Partner at TPG Biotech; Director at Intercept Pharmaceuticals, Inc.; Independent Director at ARYx Therapeutics, Inc.; Director at Biodel Inc.; President and Chief Business Officer at ARIAD Pharmaceuticals, Inc.; Independent Director at Cita NeuroPharmaceuticals Inc.; Partner at Sprout Group; and Venture Partner at MPM BioImpact LLC. He is Founder of Cerimon Pharmaceuticals, Inc. and also served as Executive Director, which he joined in 2004. He has held senior roles including Chief Strategy Officer and Group Executive Vice President of Global Business Development at Teva Pharmaceutical Industries Limited and Executive Officer at Novartis AG. His prior board and executive roles include Director at MacroGenics, Inc., KAI Pharmaceuticals, Inc., The Irvington Institute for Immunological Research and the Metropolitan Opera; Member of the Supervisory Board at Affectis Pharmaceuticals AG; and Executive Officer at Zymark Corporation and PerSeptive Biosystems, Inc. Mr. Sekhri is a highly accomplished executive with several years of leadership experience across the global life sciences industry. His career spans senior operating roles in multinational pharmaceutical companies, venture-backed biotech firms and top-tier venture capital and private equity organizations. He has served on numerous public and private company boards. Mr. Sekhri received a M.S. in Anatomy & Neuroscience from the University of Maryland School of Medicine in 1986 and a B.S. in Zoology & Molecular Biology from the University of Maryland College Park Foundation, Inc. in 1981.

Positions